Divalproex Sodium Market from 2021-2027 | Size, Share, Trends, Analysis, Growth, Top Key players and Forecast to 2027

SEATTLE, April 08, 2021, (PHARMIWEB) — Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug used to treat migraine headaches, manic episodes of bipolar disorders, and certain types of seizures. Divalproex sodium is known for its anticonvulsant properties for the treatment of epilepsy. Divalproex sodium comes under three dosage forms such as capsule, tablet, and syrup. Divalproex sodium oral tablet is available in brand-names such as Depakote ER and Depakote. Divalproex sodium have application in various combinational therapies.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1913

Moreover, recommended initial dosage of Depakote for the treatment of bipolar disorders is 750 mg daily, whereas for complex partial seizures, initial dosage starts with 10 to 15 mg/kg/day. In addition, recommended starting dose for migraine headache is 250 mg twice daily to achieve therapeutic response.

Divalproex Sodium Market Dynamics

Increasing prevalence of bipolar disorders around the globe is expected to propel the divalproex sodium market growth. For instance, according to a study published in JAMA Psychiatry Journal 2012, in a combined sample of 61,392 adults from 11 countries, the total lifetime prevalence of bipolar disorder-I was 0.6%, and 0.4% for bipolar disorder-II and sub-threshold bipolar disorder was 1.4%, yielding a total prevalence estimates bipolar disorder spectrum of 2.4% globally.

Moreover, rising patient pool around the world affected with epilepsy and migraine headaches is expected to boost demand for divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological disease, and around 80% of the people with epilepsy live in low and middle-income countries.

According to the Migraine Trust Facts and Figures estimates, global prevalence of migraine was 14.7% for year 2013 that accounts for 1 in 7 people. Furthermore, increasing awareness about diseases and various government initiatives to prevent head migraine are expected to propel growth of divalproex sodium market.

However, black boxed warning given by FDA due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablet and other known adverse reactions such as birth defects, neurobehavioral adverse effects, and suicidal behavior are expected to hamper divalproex sodium market growth over the forecast period.

Divalproex Sodium Market – Regional Insights

Based on the region, the global divalproex sodium market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America, specifically the U.S. divalproex sodium market is expected to hold a dominant position, among the regions. This is attributed to increasing government initiatives and rising research and development for the introduction of new product that are expected to drive growth of the divalproex sodium market in the region. For instance, in 2011, National Quality Strategy (NQS) was launched as the national strategy for quality improvement in health care, This was led by Agency for Healthcare Research and Quality on behalf of the U.S. Department of Health and Human Services (HHS). However, introduction of generic products by market giants in the region is expected to hamper the market growth in the region. For instance, in 2008, Mylan launched generic of Abbott’s Depakote ER in the U.S.

Asia Pacific is expected to exhibit significant growth followed by Europe, owing to increasing prevalence of epilepsy and head migraine among the population in the region. For instance, according to study published in the Journal of Global Health 2017, reported that lifetime epilepsy prevalence was 1.99% in 1990 and 7.15% in 2015 among China population.

Divalproex Sodium Market – Competitive Landscape

Major players operating in the global divalproex sodium market include Zydus Pharmaceuticals, Inc., AbbVie Inc., Mylan N.V., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Orchid Chemicals & Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1913

Market players are engaged in adopting marketing strategies such as mergers, collaborations, induction of new products to their portfolio, and acquisition, in order to obtain dominant position in the market. For instance, in 2017, Zydus Cadila acquired Sentynl Therapeutics, a U.S.-based pharma company specialized in marketing of products in the pain management segment.

Divalproex Sodium Market Taxonomy

On the basis of dosage form:

• Capsule
• Tablet
• Syrup

On the basis of application:

• Epilepsy
• Manic Depressive Illness
• Other

On the basis distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

On the basis of region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837